Inflammatory bowel disease is associated with an increased likelihood of developing lymphoma. However, it is still controversial if this risk may be attributed to the disease itself or rather represents an effect of immunosuppressive treatment. Although tumor necrosis factor alpha (TNFα) is a key cytokine for cancer immunosurveillance, the potential relationship between anti-TNFα agents and the pathogenesis of lymphoproliferative disorders remains unclear. Here, we describe the case of a patient with severe perianal Crohn's disease, treated with infliximab monotherapy, whose unusual presentation with acute groin pain required surgical intervention and led to the diagnosis of diffuse large B-cell lymphoma. However, 10 months after this episode, treatment with infliximab was restarted because the patient continued with refractory and disabling perianal disease. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains mild perianal Crohn's disease and persists in sustained clinical and imaging remission of the lymphoproliferative disorder.
Introduction
Tumor necrosis factor alpha (TNFα), a key mediator of inflammation, plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD) [1] . In fact, TNFα antagonists have become widely used and have shifted the paradigm in the management of IBD over the past few years [2, 3] . Notwithstanding, TNFα is also critical for cancer immunosurveillance and defense against infections [4, 5] ; thus, concerns have been raised regarding the use of anti-TNFα therapy and the risk of certain complications, including lymphoma [6] . Crohn's disease patients have been associated with an increased risk of lymphoproliferative disorders, especially non-Hodgkin lymphoma [7] ; however, it remains controversial whether this only represents a causal effect of immunosuppressive therapy or if IBD itself is an independent risk factor for lymphoma [8] . Although subjects with intestinal lymphomas may experience bowel complications requiring surgery, acute groin pain as the first presentation of a nodal lymphoma is extremely unlikely and has not been described before in an IBD patient. We present the case of a Crohn's disease patient, under treatment with infliximab, who was diagnosed with a nodal lymphoma after presenting with acute groin pain.
Clinical case
A 29-year-old male, with a history of recurrent perianal fistulas and abscesses, who maintained severe anal pain and perianal purulent drainage despite several surgical procedures, was referred to our center. A proctological examination under anesthesia revealed a deep ulcer in the anal canal and perianal abscess, for which incision, drainage, and seton placement were performed and antibiotics were administered. He underwent a colonoscopy that showed skip areas with decreased vascular pattern and ulceration in all colon segments and in the terminal ileum, and biopsies were taken. Histopathological analysis findings and further pelvic magnetic resonance (MR) imaging and MR enterography allowed the diagnosis of ileocolonic and complex perianal
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Crohn's disease. The patient was started on treatment with prednisolone (50 mg daily) and, given the extent and severity of the luminal and perianal involvement, a top-down strategy was adopted-infliximab 5 mg/kg was initiated (at 0, 2 and 6 weeks, and thereafter every 8 weeks) shortly after steroid initiation. In the following months, since he maintained complex and disabling perianal disease and having required several surgical procedures to unroof the fistula tracts and seton placement, infliximab dose adjustment (by shortening the infusion intervals to every 6 weeks) and its combination with hyperbaric oxygen therapy were required.
In July 2014, 17 months after anti-TNFα initiation and while in clinical remission of luminal Crohn's disease, the patient presented to the emergency department with a 5-h history of severe pain and swelling in the right inguinal region. Upon examination, a painful bulky and non-reducible mass was found, leading to the clinical diagnosis of incarcerated right inguinal hernia, for which he underwent surgery. However, surgical exploration unexpectedly revealed a highly vascularized 5-cm lymph node with a necrotic center, without any evidence of inguinal hernia. Regional lymphadenectomy was performed and resected specimens were sent for histological and microbiological evaluation. Apart from a slight increase in C-reactive protein (24 mg/L), initial laboratory studies, which also included complete blood count, erythrocyte sedimentation rate, renal and liver function tests, lactate dehydrogenase, creatine kinase and Epstein-Barr virus serologies, were unremarkable. Further histological analysis of the enlarged lymph node described the presence of architectural distortion and diffuse infiltration of large atypical lymphocytes, with irregular nuclei, some of which with visible nucleoli (Fig. 1) . The immunohistochemistry profile (CD20+, CD3−, Bcl-6+, CD10−, MUM-1−, Bcl-2−) was compatible with diffuse large B-cell lymphoma of germinal center B-cell-like subtype (Fig. 2) . The remaining resected lymph nodes did not show histological features of malignancy. Additional investigation included bone marrow biopsy, full body computed tomography (CT) scan, positron emission tomography-CT and measurement of beta-2-microglobulin, which were all normal. The post-procedure course was uneventful and he was discharged being completely asymptomatic. A multidisciplinary approach was undertaken which included representatives from the hematology team who advised that chemotherapy in a patient with persistent perianal suppuration could result in an extremely high risk of infectious complications. Therefore, given his staging (Ann Arbor stage I) and clinical features and the involvement of a single lymph node, it was decided not to perform chemotherapy. Anti-TNFα therapy was suspended and the patient was kept under observation and close monitoring. In the following months, he developed recurrent perianal supuration despite antibiotics, topical treatment and hyperbaric oxygen therapy. Approximately 10 months later, since he continued with severe and disabling perianal Fig. 1 a, b Lymph node revealing diffuse infiltration of large atypical cells, with irregular nuclei and visible nucleoli (H&E stain; a ×100, b ×400) Fig. 2 Immunohistochemistry staining for Bcl-2 (×200) involvement, the difficult decision of restarting infliximab therapy was taken, after discussion with the hematology team and careful consideration of the risks and benefits. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains mild perianal Crohn's disease and persists in sustained clinical and imaging remission of the lymphoma (Fig. 3) .
Discussion
In the Western world, there has been an upward trend in the incidence of lymphoma in the past few decades, along with a parallel increase in the occurrence of inflammatory conditions treated with immunosuppressive agents [9] . Various studies have identified an increased risk of lymphoma among patients with several chronic inflammatory disorders [10, 11] . Persistent activation of the immune system may exert a critical influence in the genesis of lymphoproliferative disorders; chronic B-cell stimulation and proliferation, in particular, appear to pose a significant threat [12] . With regard to IBD, some controversy still exists concerning the contribution of this disease to the occurrence of hematological malignancies. Although large population-based studies did not show a correlation between IBD and such conditions, a meta-analysis conducted by Pedersen et al. suggested that Crohn's disease patients would have a borderline significant increase in the likelihood of developing a lymphoma [13] [14] [15] . These latter results were corroborated by a subsequent population-based study which revealed an association between Crohn's disease and non-Hodgkin lymphoma, unrelated to thiopurine exposure [7] . Additionally, advanced age, male gender, genetic mutations, certain viral infections and, most importantly, immunosuppressive therapy, were identified as risk factors for developing lymphoproliferative disorders in IBD patients [8] . In fact, despite remaining uncertainties regarding the potential independent role of the disease itself in the pathogenesis of those disturbances, the contribution of immunosuppressive therapy is widely known. Patients treated with thiopurines were shown to have a 4-to 5-fold increase in the risk of acquiring lymphoma, with this risk being correlated with the duration of treatment and being eliminated after its cessation [16, 17] . Regarding anti-TNFα therapy, apart from the case of hepatosplenic T-cell lymphoma, for which they seem to potentiate the deleterious effect of thiopurines, there is not enough evidence to claim that these agents may contribute to lymphoma occurrence [8] . Both a systematic review of registries and prospective observational studies of rheumatoid arthritis patients and an analysis of the Crohn's Therapy, Resource, Evaluation and Assessment Tool (TREAT) registry did not verify a higher probability of such complications among subjects who underwent anti-TNFα treatment [18, 19] . Thus, in a patient like ours, who was submitted only to anti-TNFα therapy and has never been exposed to thiopurines, the possible association between treatment and these malignancies is even more doubtful.
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately one-third of adult non-Hodgkin lymphoma cases and usually presents with palpable lymphadenopathies or extranodal involvement [20, 21] . Since the gastrointestinal tract is a frequent extranodal site of involvement in nonHodgkin lymphomas (the most common in DLBCL), diagnosis often occurs following surgery for any abdominal complication, such as intussusception, acute appendicitis, bowel perforation, obstruction or even ischemia due to mesenteric thrombosis [22] [23] [24] [25] [26] . Although DLBCL frequently shows a rapid proliferation rate, it is surprising that this phenomenon could be sufficient to manifest itself as an acute phenomenom, such as in our patient, whose initial presentation with an extremely painful bulky and non-reducible mass, which started only a few hours before admission, simulated an incarcerated inguinal hernia and led to surgery.
Several authors have reported spontaneous regression of lymphoma after immunosuppressive therapy withdrawal [27] [28] [29] [30] [31] . Nonetheless, we did not find any case in the literature of anti-TNFα resumption in this setting. The available evidence is still insufficient to warrant the safety of such drugs in patients with a background of hematological malignancy. However, in a patient like ours, with persistently active and severely disabling perianal Crohn's disease, the difficult decision to reinitiate biological therapy has ensured clinical improvement without relapse of the lymphoproliferative disorder during the follow-up period.
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